Mainz Biomed announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. For more than 60 years, the Instituto de Microecologia has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis and diagnosis of microbiota profiles and specific health parameters. Entering the market and beginning commercialization in Spain and Portugal signify the continued expansion of Mainz Biomed’s impact in Europe.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
- Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
- Mainz Biomed Provides Full Year 2022 Financial Results
- Mainz Biomed B.V. (MYNZ) Q1 Earnings Cheat Sheet
- Mainz Biomed expands ColoAlert corporate health programs